original data for cimifugin
Psoriasis is an immune-mediated chronic inflammatory skin disease, which causes deleterious effects on patient quality of life. In this study, it was found that TRPV4 was involved in the formation of psoriasis pruritus, and cimifugin could significantly inhibit the itch behavior of psoriasis model mice. The expression of TRPV4 in the skin of psoriasis patients was positively correlated with the severity of psoriasis patients, and the same result was found in the psoriasis model mice. In the comparative study of psoriasis model between TRPV4 knockout mice and WT mice, it was found that the scratching behavior of TRPV4 knockout mice was significantly lower. At the same time, cimifugin could effectively inhibit the itching behavior of the psoriasis model mice, which was dose dependence. In the cell experiments of HaCaT, HEK293 and DRG, we further proved that cimifugin can effectively inhibit the cell responses induced by GSK101, a TRPV4 channel agonist, including calcium influx and inward current. Therefore, we concluded that TRPV4 is an important molecule in the formation of psoriasis pruritus, and cimifugin can alleviate the symptoms of psoriasis pruritus by inhibiting the activity of TRPV4 channel. This study provides a new idea for the clinical treatment of psoriasis pruritus. All data are expressed as mean ± SEM. Statistical analysis of the number of TRPV4-positive cells was performed manually. Comparisons between the two groups were performed using GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA). Two sets of comparisons were performed only by t-test. N.S, no meaning. *p <0.05, **p <0.01, ***p <0.001 indicates a statistically significant difference.